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Abstract 
The principal challenge for the use of boronic acids (BA) as glucose sensors is their lack 
of specificity for glucose. We examined the selectivity of and insulin release from two 
boronic acids- (2-formyl-3-thienylboronic acid (FTBA) and 4-formylphenylboronic acid 
(FPBA))  conjugated chitosan scaffolds to glucose and fructose. Adsorption of glucose 
to BA: chitosan conjugates was dose-dependent up to 1:1 at 35 and 42% for FPBA and 
FTBA respectively but the FTBA conjugates adsorbed more glucose and fructose at 
respective FPBA ratios. The affinity of both BA conjugates to glucose decreased with 
increase in BA ratio. On the other hand, the affinity of both BA conjugates for fructose 
decreased from ratio 1:1 to 2:1 then rose again at 3:1. Insulin release from FPBA 
nanoparticles (FPBAINP) and FTBA nanoparticles (FTBAINP) were both 
concentration-dependent within glyceamically relevant values (1-3 mg/ml glucose and 
0.002 mg/ml fructose). Furthermore, the total amounts of insulin released from 
FPBAINP in both the media were higher than from FTBAINP. Both FPBAINP and 
FTBAINP have the potential for development as a glucose-selective insulin delivery 
system in physiological settings. 
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1 Introduction 
As one of the most common chronic diseases in almost every country, the incidence of 
diabetes is on the rise. Maintenance of continuous normoglycaemic conditions (70–140 
mg per dl or 4–8 mM) is the key goal for the management of both type 1 and type 2 
diabetes [1]. The current treatment option for type 1 and end-stage type 2 diabetes is 
insulin replacement therapy in the form of multiple daily subcutaneous injections of 
insulin, which is discomforting and lead to poor patient compliance [2]. This has 
necessitated research interest amongst scientists working toward developing glucose-
regulated insulin replacement therapies that are painless, relatively inexpensive to 
manufacture compared to the current mode and readily available [3]. In the last two 
decades, progress has been made in the field of nanotechnology and polymer science 
whereby scientists have bioengineered nanoparticles to release the pay loaded after 
sensing changes in their surroundings [4]. Glucose-responsive insulin delivery (GRID) 
systems are designed to release insulin in response to a rise in glucose levels with a 
feedback check at normoglycaemic levels. These delivery systems have the potential to 
not only achieve tighter glycaemic control, but also eliminate the need for frequent 
finger-stick glucose tests and multiple daily insulin injections [5]. Currently, the three 
most extensively studied glucose sensors are glucose oxidase, glucose-binding proteins 
(GBPs) and glucose-binding small molecules. Using these glucose responsive 
molecules, insulin loaded nanoparticles can be formulated which will release the drug 
via degradation, disassembly or swelling in response to changes in glucose 
concentrations [4,6]. 
Small molecule glucose binders such as boronic acids (BAs) offer a chemical approach 
to glucose-mediated insulin release via reversible interactions with cis-1,2- or 1,3-diols. 
Unlike glucose oxidase and GBPs, BAs offer the advantages of having fast response 
rates, being oxygen-independent and causing no immunological responses. However, 
their lack of glucose specificity has been the major drawback for their use as glucose 
sensors in GRIDs. It has been shown that monoboronic acids have the highest 
selectivity for fructose among all the saccharides [7]. This is because the β-D-
fructofuranose (Fig.1a) binds to boronic acids and is available as 25% of total fructose 
in D2O at 31ºC. On the other hand, the α-D-glucofuranose (Fig.1b) form of glucose 
binds to boronic acids, constituting only 0.14% of the total glucose in D2O at 27ºC [8].  
This poses a constraint for monoboronic acids acting as glucose-specific sensors in 
systemic insulin delivery systems because blood has both glucose and fructose and 
insulin release due to the presence of fructose is undesirable in the present context. 
However, the problem can be overcome by using suitably positioned multiboronic acids 
anchored on a polymer backbone. Multiboronic acids as glucose-specific sensors are 
similar to biological sensors like lectins as they have multiple binding sites. Over the 
last ten years, scientists have proposed several glucose-specific multiboronic acid 
scaffolds. Currently, four main strategies are being widely investigated which include 
synthetic diboronic acids, boronic acid-conjugated polymers, self-assembly of simple 
boronic acids and boronic acid-conjugated nanomaterials [8].  
In the present investigation, multiboronic acid scaffolds are formed from a chitosan 
backbone and studied with regard to their specificity for glucose sensing and subsequent 
release of insulin in response. In an attempt to address the lack of specificity to glucose 
sensing by boronic acids, we report for the first time, the use of 2-formyl-3-
thienylboronic acid (FTBA) as the boronic acid conjugated to chitosan in the 
development of a glucose chemosensor. Since phenylboronic acids have been widely 
investigated as glucose sensors, 4-formylphenylboronic acid (FPBA) was chosen for 
comparative studies in this investigation. Equally important is the physical and chemical 
properties of the scaffold anchoring macromolecule. Chitosan was used as the 
multiboronic acid anchor in the present study because it is biocompatible, 
biodegradable, non-toxic and retains a significant level of hydrophilicity relevant for in 
vivo applications. Furthermore, it is relatively simple and easy to formulate as 
nanoparticles via polyelectrolyte complexation [9,10]. As the nanoparticles form 
spontaneously in aqueous media with high encapsulation efficiencies, there is no need 
for the use of additional solvents or heating, hence eliminating concerns of cytotoxicity 
and insulin instability [11,12]. The organic reaction used to conjugate the boronic acids 
to chitosan is reductive N-alkylation.  
2 Materials and methods 
2.1. Materials 
Low molecular weight chitosan, 2-formyl-3-thienylboronic acid (FTBA), 4-
formylphenylboronic acid (FPBA), sodium borohydride, glucose hexokinase assay kit 
and curcumin were purchased from Sigma Aldrich (St. Louis, MO, USA); acetic acid, 
methanol, acetonitrile, fructose and glucose were purchased from Thermo Fischer 
Scientific (Bridgewater, NJ, USA); human recombinant zinc insulin from P. pastoris 
(28.5 IU/mg) was obtained from Merck (Whitehouse, NJ, USA). All other chemicals 
were of reagent grade. 
2.2. Synthesis and purification of boronic acid-chitosan conjugates 
50mg of chitosan (dissolved in 1% acetic acid) and various molar equivalents of FPBA 
and FTBA (Table 1) were mixed and stirred in separate clean beakers containing 15 ml 
of methanol. After 3 hours, sodium borohydride (1.6 x the molar equivalences of FPBA 
and FTBA) was added in respective beakers and the mixtures were allowed to stir for a 
further 10 mins. Afterwards, the reaction was quenched with 1 M sodium hydroxide. 
The precipitates formed were centrifuged at 6000 rpm for 10 mins and washed 
thoroughly with methanol, ethanol and water to remove any traces of unreacted BAs. 
The conjugates were then lyophilised and stored in 2
o
C for use in further studies. 
2.3. Glucose adsorption studies 
10 mg of pure chitosan (control) and 10 mg of the various ratios of the conjugates were 
exposed to 1 ml of 2 mg/ml glucose solution in Eppendorf
®
 tubes separately. The tubes 
were placed in an incubator shaker operated at 100 rpm and maintained at 37ºC for 1hr 
of equilibration. Afterwards, the mixtures were centrifuged at 10,000 rpm for 2 mins 
and the supernatants collected to determine the amount of glucose present via HPLC. 
The amount present in the supernatant subtracted from the original amount present in 
the tubes would give the amount of glucose adsorbed by the conjugates.  
The HPLC analysis was carried out by first preparing standard solutions of glucose 
ranging from 0.25 – 10 mg/ml. 10 µl of each of the glucose solutions was mixed with 
1ml of hexokinase reagent (in excess) in HPLC vials. The mobile phase consisted of 20 
mM potassium dihydrogen phosphate and acetonitrile (95:5). The elution was isocratic 
with a flow rate of 1 ml/min, whilst the injection volume was 20 µl and detection 
wavelength was 340 nm. The column used was Phenomenex Jupiter
®
 C18 with pore size 
of 300 Å.  
2.4. Boronic acid specificity for diols (glucose and fructose) 
The affinities of the two boronic acids for glucose and fructose were studied using an 
indirect and novel HPLC technique based on colour changes of curcumin after reaction 
with boronic acid. The method is based on the premise that curcumin reacts with 
boronic acids in solution to form a complex called rosocyanine. During this reaction, the 
colour changes from yellow (curcumin) to bright red (rosocyanine) and both the colours 
can be determined spectrophotometrically [13]. 10 mg of conjugates (ratios 1:1, 2:1 and 
3:1) were equilibrated with 1 ml of 2 mg/ml glucose and fructose solutions in 
Eppendorf
®
 tubes placed in an incubator shaker at 100 rpm and 37ºC. Control tubes had 
the conjugates exposed to 1 ml of milli-Q water only. After 1 hour, 500 µl of 0.1 mg/ml 
curcumin solution (dissolved in methanol) was added in each of the tubes and shaken 
gently for a few seconds. The following reactions summarise the events that take place 
after addition of curcumin: 
 
 
 
 
In the control, where curcumin is added after exposure of the conjugates to milli-Q 
water only, curcumin interacts with all the available boronic acid moieties on the solid 
conjugates at the bottom of the tube. Since curcumin is present in excess, there is 
always free curcumin in solution. In the sample tubes, where the conjugates have been 
equilibrated with glucose or fructose, boronic acid moieties interact with the diols with 
varying degree of affinities. Consequently, fewer boronic acid moieties are available for 
interaction with curcumin. This also means that if the same amount of curcumin (as that 
in control) is added to the sample tubes, the amount of free curcumin in solution will be 
higher in the sample tubes. Since curcumin can be detected via UV-spectroscopy at 425 
nm, the difference in the absorbance between the two respective ‘free curcumin’ 
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solutions will give an indication of the degree of affinity of the conjugates for the two 
diols. This procedure is sensitive and has not been reported elsewhere. 
The HPLC analysis was carried out by first preparing five standard solutions of 
curcumin ranging from 1 - 50 µg/ml. The mobile phase consisted of acetonitrile, 0.01% 
acetic acid and methanol in the ratio 53:42:5. The elution was isocratic with a flow rate 
of 1.5 ml/min. The injection volume was 10 µl and the detection wavelength was 425 
nm. The column used was Agilent Zorbax 300SB-4.6 x 250 mm C18, with particle size 
of 5 μm and pore size of 300 Å. To calculate the absorbances of ‘free curcumin’ with 
and without the presence of diols, the mixtures were centrifuged at 14,000 rpm for 2 
mins and 10 µl of the supernatants were directly injected into the HPLC system. 
2.5. Formulation of insulin loaded boronic acid-functionalised chitosan 
nanoparticles 
FPBA or FTBA chitosan conjugates (chitosan:boronic acid = 1:1) was  dissolved in 1% 
acetic acid to a concentration of 1.5 mg/ml and the pH adjusted to 4.2 using 1 M NaOH. 
Insulin (dissolved in 0.01 N HCl) was mixed with TPP (0.5 mg/ml) to give a final 
concentration of 0.3 mg/ml and then added dropwise to the conjugate solutions under 
magnetic stirring to prepare the two nanoparticulate formulations – FPBAINP and 
FTBAINP. 
2.6. Physical properties of the nanoparticles 
The size (z-average), polydispersity index (pdi) and charge (zeta potential) of the 
nanoparticles were assessed using a Zetasizer Nano ZS (Malvern, UK) equipped with a 
4 mW He-Ne laser (633 nm). Each analysis was carried out at 25 °C, performed in 
triplicate and the data expressed as mean ± standard deviation. The morphology and 
surface topography of the nanoparticles was performed on a field emission scanning 
electron microscope (FESEM, Quanta 400F, FEI Company, Fremont, CA, USA) under 
low vacuum and at a viewing voltage of 20.0 kV. After a 1:10 dilution with deionized 
water, a drop of freshly prepared nanoparticulate solution was placed onto an SEM 
imaging stub and left to air-dry at room temperature for 24 hours before viewing. 
2.7. In vitro insulin release studies 
The amount of insulin released from the nanoparticles was studied in deionised water, 
glucose (1, 2 and 3 mg/ml), fructose (0.002 mg/ml) and a mixture of glucose (2 mg/ml) 
and fructose (0.002 mg/ml). Several 100 µl replicas of FPBAINP and FTBAINP were 
placed in Eppendorf tubes containing 1 ml of the various media incubated at 37ºC with 
horizontal shaking at 100 rpm on a WiseCube WIS-20, Precise Shaking Incubator. At 
predetermined time points, one of the seeded tubes was withdrawn and centrifuged at 
14000 rpm for 5 mins (Beckman Coulter Microfuge 16 centrifuge) followed by direct 
injection of 20 μl of the supernatant onto the HPLC system. The amount of insulin 
released in the respective media was computed by comparing peak areas obtained with 
those from the calibration curve. 
The HPLC system consisted of an Agilent UV detector (214 nm) linked to an Agilent 
pump operated by gradient elution:  0.1% aqueous triflouroacetic acid (TFA) (A) and 
0.1% TFA in acetonitrile (B), with 75% of A and decreased to 40% over 7 min at 1 
ml/min using an Agilent Zorbax 300SB-4.6 x 250 mm C18 column, with particle size of 
5 μm and pore size of 300 Å. The injection volume was 20 µl. The calibration curve 
was constructed from pure insulin dissolved in 0.01 N HCl at a range of 1 - 100 µg/ml. 
2.8. Evaluation of Encapsulation Efficiency and Loading Capacity of Nanoparticles 
The encapsulation efficiency (EE%) and loading capacity (LC%) of insulin within the 
nanoparticles were determined upon separation of the nanoparticles from the aqueous 
medium containing free insulin by centrifugation at 14,000 rpm for 45 mins using a 
Beckman Coulter Microfuge 16 centrifuge (Beckman Coulter, Brea, CA, USA). The 
amount of free insulin in the supernatant was measured using the above HPLC 
procedure for insulin by comparing peak area obtained with that from the calibration 
curve. All samples were run in triplicate. The EE% and LC% for insulin were calculated 
as: 
EE% =  
total insulin in formulation−free insulin in supernatant
total insulin in formulation
 ×  100       
(1)LC% =
total insulin in formulation− free insulin in supernatant
weight of nanoparticles
 ×  100        (2) 
 
2.9. Statistical Analysis 
A simple two-tailed t-test was performed with 95% confidence interval to check for 
significant differences between experimental results where necessary. 
3 Results and Discussion 
3.1. Glucose adsorption study 
HPLC analyses were carried out to confirm the conjugation of BAs to chitosan through 
glucose adsorption estimation. Pure chitosan will adsorb very little to no glucose, 
however, boronic acid conjugated chitosan will adsorb glucose due to the interactions 
between boronic acid and the hydroxyl moieties of glucose. It is extremely difficult to 
directly determine glucose via UV-spectroscopy hence glucose hexokinase reagent was 
used for an indirect estimation. In this reaction, glucose hexokinase phosphorylates 
glucose to glucose-6-phosphate (G6P) which in turn is oxidised to 6-phosphogluconate 
(6PG) by glucose-6-phosphate dehydrogenase (G6PD). During the latter reaction, 
NAD
+
 is reduced to NADH which can be determined via UV-spectroscopy at 340 nm. 
Since the amount of NADH produced is directly proportional to the amount of glucose 
during the entire reaction, the hexokinase assay can give us the amount of glucose 
adsorbed by the conjugates.   
Fig.2 shows the percentage glucose adsorption at the various ratios of the two boronic 
acid-chitosan conjugates. Boronic acid is the entity that reversibly binds to glucose, 
hence pure chitosan adsorbs very little to no glucose. The data clearly shows that the 
conjugates adsorb glucose. 
It can also be seen that, for both the boronic acids, as the ratio of boronic acid to 
chitosan increases, the glucose adsorption also increases albeit to ratio 1:1. This result is 
similar to those obtained by Asantewaa et al. [9] who conducted their investigation 
using FPBA only. It can be hypothesised that at ratios below 1:1, there is insufficient 
boronic acid moieties within the conjugates to adsorb glucose. Ratio 1:1 appears to 
provide the optimum number of moieties for maximum adsorption of glucose for the 
two conjugates. Aptly, at ratios above 1:1, the number of boronic acid moieties on the 
chitosan backbone increases, however, that also increases the crystallinity of the 
conjugates [9]. As more and more boronic acids attach to the chitosan backbone, the 
close packing arrangement makes the structure increasingly rigid. As the two hydroxyl 
moieties at 1,2- and 3,5,6-positions of α-D-glucofuranose (fig.1) are spread out in 
different domains, a flexible polymer backbone with reasonably spaced boronic acid 
moieties is required for effective multivalent binding between boronic acids and glucose 
[8]. This phenomenon might be one of the fundamental reasons as to why the adsorption 
of glucose decreases above a threshold ratio. Furthermore, the FTBA conjugates (at all 
ratios) had a higher percentage of glucose adsorption at respective FPBA ratios 
(significant, p<0.025). In FPBA (Fig.3a) the chitosan monomers conjugate with the 
boronic acids at position 4 of the benzene ring, while in FTBA (Fig.3b), the conjugation 
takes place at position 2 of the thienyl ring. Due to the proximity of the thienyl rings of 
FTBA and the cyclohexane rings of chitosan to the glucose molecule as it forms the 
complex with boronic acid, it can be postulated that additional C-H•••π interactions 
might contribute to a slightly higher affinity (and hence greater adsorption) of FTBA to 
glucose compared to that of FPBA. 
3.2. Specificity of boronic acids for glucose and fructose 
The idea of using curcumin to ascertain the relative affinities of the two boronic acid-
conjugated polymers for glucose and fructose in this project was envisaged to explore a 
novel way of studying the extent of adsorption between boronic acids and diols. 
Curcumin can be used to detect boron at very low (ppm) levels [13], so the slightest 
change in boronic acid concentrations due to complexation between glucose or fructose 
can be determined using this dye. A higher amount of free curcumin in solution of an 
experimental (glucose/fructose) sample compared to that in a control (no diol) sample 
will indicate the complexation between boronic acids and diols. Furthermore, the 
difference in free curcumin levels between the diols gives us an estimation of the 
relative affinities of the boronic acids for glucose and fructose. Fig.4 portrays the results 
obtained from this investigation. Since glucose adsorption with the conjugate at 1:1 
ratio manifested the highest adsorption of glucose (from section 3.1), this conjugate was 
selected for further investigation. To substantiate our claim that increased crystallinity 
and/or lack of flexibility within the boronic acid-chitosan scaffolds at higher ratios 
decreases the sensitivities of the conjugates to glucose adsorption, ratios 2:1 and 3:1 
were also investigated. 
It can be seen from Fig.4a that, in the presence of glucose, the amount of free curcumin 
in solution decreases at conjugate ratios above 1:1. This means that at ratios above 1:1, 
more curcumin is involved in complexing with boronic acids. So, it can be deduced that 
fewer glucose molecules are occupying the available boronic acid binding moieties at 
higher ratios; in other words, the affinity of the boronic acid-chitosan conjugates for 
glucose is decreasing. This observation is in concordance with the previous glucose 
adsorption data in section 3.1 and supplements the proposition that lack of flexibility in 
the polymeric scaffolds at higher boronic acid:chitosan ratios might be the principal 
reason for the decreased affinity of glucose. Additionally, it should be noted that the % 
free curcumin in solution at all FTBA ratios is significantly higher than at 
corresponding FPBA ratios (p<0.025). Hence, we may conclude that the FTBA 
conjugates have greater affinity for glucose than FPBA scaffolds and the notion 
(presented in section 3.1) that the interactions between the thienyl rings (of FTBA), 
cyclohexane rings (of chitosan backbone) and the hydrocarbon skeleton of glucose is 
the reason behind the higher propensity for adsorption of glucose by FTBA appears to 
be the plausible explanation. 
On the other hand, the data with fructose (Fig.4b) contrast those with glucose. Here, the 
affinity of both types of the boronic acid conjugates for fructose appears to decrease 
from ratio 1:1 to 2:1. SEM studies conducted by Asantewaa et al. [9] indicate that at 
ratios above 1:1, the conjugates become less porous and more crystalline with flat 
surfaces. Consequently, with increase in crystallinity, the surface area:volume ratio 
decreases which impedes effective interaction between fructose and boronic acids. 
However, the affinity of boronic acid conjugates for fructose rises again at 3:1 which is 
a contradiction to the theory put forward by Asantewaa et al [9]. This takes us back to 
the topic of monovalent interactions of fructose with boronic acid (section 2.1). Wu et 
al. [8] identified that fructose acts as a monovalent ligand (Fig.3c) in almost all sensing 
studies performed with boronic acids.  
Unlike glucose, which has two diol groups involved in multivalent binding with two 
boronic acid moieties and thus requiring a flexible polymer backbone, fructose appears 
to overcome the challenge imposed by increased crystallinity with its monovalent 
interactions capability. One molecule of fructose can bind with one boronic acid moiety, 
so at higher conjugate ratios where the number of boronic acids attached to chitosan is 
higher, more fructose molecules come together and attach to boronic acids side by side.   
Additionally, at ratio 1:1, the specificity of both FPBA- and FTBA-chitosan scaffolds 
for glucose is highest (7.58% and 20.73% higher level of free curcumin in solution 
respectively). It can be posited that this is the optimum ratio where the conjugates have 
the ideal number of boronic acids for effective multivalent interactions with glucose. 
Multivalency, in chemical and in biological systems, is a key concept which means that 
when two multivalent moieties are involved in n binding events (n>1), the binding 
occurs with higher affinity than the sum of n individual monovalent bindings. 
According to fig.1, fructose has one binding moiety while, glucose has two (at the 1,2- 
and 3,5,6-positions). Consequently, monoboronic acids with one binding moiety interact 
with greater affinity with fructose since monovalent interactions take place here. 
However, in di- or multiboronic acids, there are at least two boronic acid moieties 
available for interaction with one glucose molecule, and hence this interaction is 
substantially stronger than monovalent interactions which take place with fructose [8]. 
We should also note that both the glucose and fructose concentrations in this 
investigation were kept the same (2 mg/ml). While this is a realistic glucose 
concentration in biological settings, the fructose concentration in the human blood is a 
thousandth less [14,15]. Considering the fact that the ultimate aim of this project is to 
develop a GRID for diabetic patients, it can be asserted that both types of boronic acid-
chitosan conjugates, designed in this study, are glucose selective at physiologically 
relevant glucose concentration. 
3.3. Insulin-loaded chitosan-TPP nanoparticles 
As boronic acid:chitosan ratio of 1:1 has proved to induce the highest glucose 
adsorption and possess the highest glucose specificity in the previous sections, this ratio 
of conjugate was chosen to prepare the chitosan-TPP nanoparticles. Table 2 shows the 
size, charge and pdi of the two types of nanoparticle formulations. Overall, the average 
diameters of the target nanoparticles – FPBAINP and FTBAINP – are reasonably small 
and the formulations are homogenous (as indicated by the pdi value). The small size of 
the nanoparticles is relevant to this investigation as it ensures a large surface area to 
volume ratio, which in turn should improve sensitivity. Nanoparticles with a surface 
charge of |10| mV are considered approximately neutral; while nanoparticles with zeta 
potentials of at least |30| mV are considered strongly ionic, thereby ensuring sufficient 
repulsive forces to keep the particles apart [16]. In that respect, the overall charges of 
the formulations are slightly on the lower side. Notwithstanding, FPBAINP and 
FTBAINP appear to be reasonably separated from each other as shown in the FESEM 
images in Fig.5. The particles also appear spherical and in agreement with the z-average 
determinations. 
3.4. Entrapment of Insulin within Chitosan Nanoparticles 
The drug release profile and pharmaceutical cost-effectiveness of a formulation depend 
on the drug loading capacity or the encapsulation efficiency (EE %) within the carrier 
system. This is particularly crucial for nanoparticulate delivery systems which have the 
smallest surface area-to-volume ratio of all dosage forms. The EE% for FPBAINP and 
FTBAINP were 56.7% and 57.5% respectively. There is a range of reported EE% of 
insulin in nanoparticulate drug delivery systems. Zhang et al. [17] reported an insulin 
loading capacity of more than 78% in their polyethylene grafted chitosan nanoparticles, 
whilst Zhu et al. [18] prepared PEG modified N-trimethylaminoethylmethacrylate 
chitosan nanoparticles which resulted in a range of EE% from 10 – 84% depending on 
the initial weight of the polymer used in the formulation. Wu et al. [19] formulated 
nanoparticles with an EE% ranging from 49 – 59% and contend that this variability was 
attributed to the amount of insulin used and the molecular weight of the polymer. We 
may conclude that the EE% obtained in the present investigation is at least comparable 
to those reported in the literature. The LC% for FPBAINP and FTBAINP were 
calculated to be 45±1.4 mg and 48±1.1 mg of insulin in 100 mg of nanoparticles 
respectively. 
3.5. In vitro insulin release in various media 
In section 3.2, we have discussed the superior specificity of FPBA- and FTBA-chitosan 
conjugates (at BA:chitosan ratio of 1:1) for glucose compared to fructose through a 
review of  the chemistry of the conjugates in the presence of the diols. The current 
section is aimed at substantiating the selectivity of the two conjugates for glucose via 
the physiochemical properties of the nanoparticulate formulations of the scaffolds. 
Three representative blood glucose concentrations were used to study the glucose 
dependency for insulin release; deionised water was used to investigate the natural 
diffusion of insulin from the nanoparticles; representative blood fructose concentration 
(diabetic) was used to investigate the influence of fructose on insulin release and a 
mixture of glucose and fructose was used to confirm glucose specificity of the boronic 
acid chitosan scaffolds. Fig.6a and b show the insulin release profiles of the two 
nanoparticle formulations in the six media investigated. In FPBAINP (Fig.6a), an initial 
burst phase of insulin release followed by a more sustained release was observed in all 
media. The burst phase can be attributed to the release of insulin that is entrapped 
toward the edge of the nanoparticulate matrix. The sustained release is of the insulin 
that is present within the deeper pockets of the core matrix. However, the amount of 
insulin released during the burst phase varied depending on the external media. 
A similar pattern of insulin release was observed in FTBAINP formulation as well. In 
both FPBAINP and FTBAINP, the amount of insulin released within the first 10–20 
mins increased as the concentration of external glucose media increased from 1 – 3 
mg/ml. In fact, within the first 20 mins the amount of insulin released from both the 
formulations in glucose media (3 mg/ml) was at least twice that in glucose media (1 
mg/ml). Springsteen et al. [20] noted that at higher glucose concentrations, the rate of 
interaction between glucose and boronic acid is higher. We believe that insulin release 
is preceded by swelling of the scaffolds caused by an increased level of interactions 
between boronic acid and glucose. This confirms the glucose concentration-dependent 
insulin release potential of the nanoparticles. 
The total amount of insulin released after one hour is identical in both FPBAINP and 
FTBAINP. Both formulations have minimal leakage as the total amount of insulin 
released in deionised water after one hour is below 4%. Interestingly, the total amount 
of insulin released from FPBAINP in fructose is higher than that released from 
FTBAINP in the same media. This observation might be the result of a relatively 
limited number of interactions between fructose and FTBA moieties than with FPBA 
moieties and hence allude to the fact that FTBA has lower affinity for fructose than 
FPBA. This observation was also noted in the raw conjugates and has significant 
implications in developing a GRID. It should also be noted that the amount of insulin 
released from both the formulations in fructose (of blood concentration) is similar to 
that released in deionised water and/or glucose (1 mg/ml). Furthermore, in glucose + 
fructose media, the total amount of insulin released from both the systems is similar to 
that released in 2 mg/ml glucose media. Considering the fact that both media had the 
same concentration of glucose and the only difference was the (blood concentration) of 
fructose, it can be concluded that both FPBAINP and FTBAINP have the potential for 
glucose selectivity in physiological settings. The presence of physiological 
concentrations of fructose does not appear to have a marked effect on insulin release 
from the two systems.  
 
4 Conclusions 
Both boronic acid-chitosan conjugates and nanoparticles were sensitive to glucose in 
biologically relevant settings, with 2-formyl-3-thienyl boronic acid possessing slightly 
higher affinity for glucose. Boronic acid-chitosan ratio of 1:1 proved to possess the 
highest glucose selectivity and was be used to conduct insulin nanoparticle formulation 
and release studies. Both systems released insulin predominantly in the presence of 
glucose. We have shown separately that the release of glucose is preceded by expansion 
of the nanoparticles arising from primary interactions between boronic acid moiety and 
diols [10].  We may conclude that the presented systems have significant potential for 
development and application as GRID systems. 
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FIGURES 
 
Figure 1: Potential boronic acid binding sites with (a) fructose and (b) glucose.  
 
 
Figure 2: Glucose adsorption of FPBA and FTBA conjugates 
 Figure 3: Structures of α-glucofuranose complex with (a) FPBA-chitosan and (b) 
FTBA-chitosan conjugates and (c) β-fructofuranose with FPBA-
chitosan. 
 
 
Figure 4: Selectivity of FPBA- and FTBA-chitosan conjugates in (a) glucose and 
(b) fructose media in terms of amount of free curcumin (%). 
 
 
 Figure 5: Scanning electron microphotography of (a) FPBAINP and (b) FTBAINP
  
 
Figure 6: Insulin release profiles of (a) FPBAINP and (b) FTBAINP in various 
media. 
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